TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Mean difference for cSBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: heart failure-related hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of at-risk women with a 6-month EPDS score >= 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean 6-month EPDS score for at-risk women
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean 6-month EPDS score for all women
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: abnormal translation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inter-eye variability in osmolarity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Enhanced performance in anterior segment maneuvers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Reduction in occipital cortical thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improvement in HAM-A scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PF 1+2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Extravasation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Re-operation rate
Endpoint domain: Adverse events/effects
Primary endpoint: Vertical navicular height increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: height gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: insulin-like growth factor-I levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative blood loss within 24h postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Platelet inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Levels of platelet-associated miRNAs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of NLRP3 gene
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum levels of IL‐1β cytokine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum levels of IL‐18 cytokine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of time in stable housing
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Proportion of women attending for a Pap test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: increased perceptual sensitivity 'd prime' (d')
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduced omission errors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: faster reaction times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac mass index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Systolic and diastolic blood pressure (BP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma nitric oxide (NO) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of ORA power over 1.00 D
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative incidence for locoregional recurrences
Endpoint domain: Mortality/survival
Primary endpoint: Reliability of medication management device
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Desire to use the machine in the future
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: DA increase in the defective visual field
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in NEI-VFQ subscale 'general vision'
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: incidence of cognitive deficits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Fluctuations in mood and anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean total procedure time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: preference for method in the future
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Perceptions of comparative advantage
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: cleaning quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in skin erythema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reduction in diaper rash
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: mean peak flow velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: functional erection without injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rPFS (radiographic progression-free survival)
Endpoint domain: Mortality/survival
Primary endpoint: QT interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: QTD and QTcD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Days covered per month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence (80% or more days covered)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean response time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: psychopathology
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pain scores upon movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CPT‐11 maximum concentrations (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CPT‐11 area under the plasma concentration versus time curves (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean terminal half‐life of CPT‐11
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep duration scores
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: resting HR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: high sensitive C-reactive protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: physical health status improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mental health status improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Risk of death for children aged 1‐59 months
Endpoint domain: Mortality/survival
Primary endpoint: Death rate from diarrhoea
Endpoint domain: Mortality/survival
Primary endpoint: Overall empowerment score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Symptom cluster severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Observed Inhaler Technique Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhaler Technique Knowledge Test Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical remission rate at Week 60
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pregnancy-specific estimated average glucose (PeAG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: time to first insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain improvement
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Antenatal emotional attachment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Perception of the fetus
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Disease-specific mortality
Endpoint domain: Mortality/survival
Primary endpoint: Grade 3 Hand-foot skin reaction (HFSR)
Endpoint domain: Adverse events/effects
Primary endpoint: prevention of the progress of left ventricular hypertrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: significant improvement rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lowering glucose concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to discharge from recovery room
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Treatment success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: FMD (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Glucose response AUC(0-240)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in frequencies of hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Reduction in frequencies of emergency visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Estimated days spent for hospital-care
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: repair halftime for laryngeal oedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: repair halftime for skin telangiectasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: repair halftime for subcutaneous fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Persistence of significant bacteriuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reducing depressive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improving patient health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Motor Function Measure first dimension subscore decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QALYs per patient
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Concentration of plasma cyclic GMP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemoglobin A1C (A1C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hypoglycemic rate
Endpoint domain: Adverse events/effects
Primary endpoint: Depression score improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: incidence of acute exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: symptom scores for cough, sputum, dyspnea
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: bacterial clearance rate in sputum cultures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: serum gastrin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: plasma motilin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: somatostatin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Fluorophotometric outflow facility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: percentage of weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvements in treadmill fitness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: grams of alcohol consumed at follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differences in metabolic profile including exaggerated dyslipidaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: DART score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfactory haemostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Treatment tolerability
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: submaximal response to exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-hour MAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 24-hour PP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 6-m walk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: early death
Endpoint domain: Mortality/survival
Primary endpoint: Improvement in coordination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: alcohol use initiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: binge drinking initiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: level of stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post‐traumatic stress disorder incidence
Endpoint domain: Adverse events/effects
Primary endpoint: behavioral performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cortical activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Health risk factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monthly absenteeism days
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Work performance scale
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Peak Ejection Rate (PER)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Peak Filling Rate (PFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: average decrease in visual analog scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transient impairment of internal anal sphincter function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline NSA-16 total score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean decrease in PANSS Negative Symptom Factor Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 40-month disease-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Lumbar muscle function normalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anastomotic stenosis after three months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: time of abdominal drainage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: amount of abdominal drainage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: mean duration of electrocoagulations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Reduction in ziprasidone AUC(0,12 h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in ziprasidone Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in ziprasidone half-life
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: theophylline metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glasgow Outcome Scale‐Extended Pediatric Revision
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: surgical field visualization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: change in intent to inquire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of new cerebral embolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Resolution of LA thrombi
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cardiac output reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Systemic vascular resistance increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: plasma and RBC folate concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Average platelet inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: haemodynamic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: sports activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Apoptotic lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: length of hospitalisation
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Retention of newly acquired word knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean time to epithelial healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of gas evacuations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Flatulence reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abdominal distension reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rates of medical abortion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Density of Foxp3 cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Density of TLR4 cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Ratio of Foxp3 mRNA to Foxp3 cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Survival Rate (SR) of restorations
Endpoint domain: Mortality/survival
Primary endpoint: Cognitive impairment and probable dementia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Acceptability of bowel preparation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Nausea as a side effect
Endpoint domain: Adverse events/effects
Primary endpoint: morbidity rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cure rate after 5 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Foot-volumetric parameters (calf pump function and venous reflux)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MDA concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: CEC count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: EPC count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total Cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: risk of confirmed disability progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean cumulative numbers of gadolinium-enhancing lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myocardial strain during systole and diastole
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in isometric strength of wrist extensors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ARAT total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in wellbeing
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: improvement in recovery
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: 12-month progression-free survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: objective response rates (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: degree of discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medical measures improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alcohol measures improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Employment measures improvement
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Housing measures improvement
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: hypoglycemic confidence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence and severity of POST
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HCG incidence rate ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: PA binding to corneal epithelial cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes